Search
Search filters
Type
Audience
Category
Issue
Last updated
- 20231 results available
- 20222 results available
- 20218 results available
- 20191 results available
- 20162 results available
- 20141 results available
- 20124 results available
- 20092 results available
- 20074 results available
- 20065 results available
- 20057 results available
- 20044 results available
- 20032 results available
- 20025 results available
- 20011 results available
Displaying 16 - 30 of 49 items.
Archived – Health Canada advises to stop using AstraZeneca Xylocaine 2% Jelly Single Use Plastic Syringes due to potential health risks
AlertPublic advisory | 2006-09-27
Archived – Important Safety Information Regarding Medication Errors Resulting From Confusion Between Seroquel and Serzone-5HT2 – AstraZeneca and Bristol-Myers Squibb – For the Public
AlertHealth professional risk communication | 2002-10-31
Archived – Important Safety Information Regarding Medication Errors Resulting from Confusion Between Seroquel® and Serzone-5HT2® – AstraZeneca and Bristol-Myers Squibb
AlertHealth professional risk communication | 2002-10-31
Pulmicort Turbuhaler (budesonide) powder for oral inhalation - Potential device failure - For Health Professionals
AlertHealth professional risk communication | 2012-07-26
Pulmicort Turbuhaler (budesonide) powder for oral inhalation - Potential device failure - For the Public
AlertHealth professional risk communication | 2012-07-26
CAPRELSA (vandetanib) - Serious Risk of Abnormal Heart Rhythm - For the Public
AlertHealth professional risk communication | 2012-02-15
Archived - Iressa (gefitinib) 250 mg Tablets - Advisories, Warnings, and Recalls for Health Professionals
AlertHealth professional risk communication | 2006-06-05
Important Safety Information on IRESSA (gefitinib) - For Health Professionals
AlertHealth professional risk communication | 2007-10-11
Archived - Safety information regarding topical anesthetics and serious adverse events - For the Public
AlertHealth professional risk communication | 2009-03-05
Iressa (gefitinib) 250 mg Tablets - Advisories, Warnings and Recalls for Health Professionals
AlertHealth professional risk communication | 2005-08-26
Archived - For the Public - Important Safety and Efficacy Information on Iressa (gefitinib) 250 mg Tablets
AlertHealth professional risk communication | 2006-08-26
Archived - Iressa (gefitinib) - Advisories, Warnings, and Recalls for Health Professionals
AlertHealth professional risk communication | 2006-12-12
CAPRELSA (vandetanib) - Serious Risk of Abnormal Heart Rhythm - For Health Professionals
AlertHealth professional risk communication | 2012-02-15
Archived – Important Safety Information Regarding the Association Between CRESTOR (Rosuvastatin) and Rhabdomyolysis
AlertHealth professional risk communication | 2004-06-22
Important Safety Information on Xylocaine (Lidocaine HCI) Jelly 2% Single Use Plastic Syringe (10 mL): Update Notice to Hospitals
AlertHealth professional risk communication | 2007-08-07